{
  "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5",
  "docSlug": "adb5c4514a6016378ffb63c7d4422971",
  "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides",
  "authorId": "tcr2-therapeutics",
  "authorName": "TCR2 Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 34,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Includes a list of abbreviations at the bottom.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/4",
  "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5",
  "deckJsonHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5.json",
  "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.63,
        "y": 0.2
      },
      "kind": "callout",
      "text": "Baseline Established: Additional strategies in Phase 2 to improve profile (CPI combo, redosing, earlier lines)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bac0eba-7c51-49fc-a071-97e412dd79fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "DCR, Disease Control Rate; ORR, Overall Response Rate; PFS, Progression Free Survival; OS, Overall Survival; RP2D, Recommended Phase 2 Dose; AE, Adverse Event; CRS, Cytokine Release Syndrome; MPM, Malignant Pleural/Peritoneal Mesothelioma; CPI, Checkpoint Inhibitor; NSCLC, Non-Small Cell Lung Cancer; MSLN, Mesothelin",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fd40458-77d8-4467-a8c8-61c64990cff4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "Efficacy Data: 93% tumor regression, 77% DCR, 29% ORR in ovarian, 21% ORR in MPM, 5.6 PFS/11.2 OS in MPM",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e5df1a5-de62-44b0-b77e-4bfc288aa45d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.03,
        "y": 0.68
      },
      "kind": "list",
      "text": "Path Forward: Ovarian focus, MPM frontline potential, NSCLC expansion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e2da0bb-5a8a-4900-96d7-ab297ee27efb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "list",
      "text": "Safety Data: RP2D manageable/reversible, 15% Grade 3+ CRS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afbfcad9-2b22-4a4a-aae7-89fbfbffbd47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 1 Key Takeaways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91ac729e-825d-4f1b-a123-c3d700f4b0c5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b0bb7b38-e899-439b-ace3-5b30d095ab39",
      "evidence": "list/bullet: Efficacy Data: 93% tumor regression, 77% DCR, 29% ORR in ovarian, 21% ORR in MPM, 5.6 PFS/11.2 OS in MPM",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 1,
      "beatId": "e67d52bc-420b-4172-85e1-cae1feae21d6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document introduces the problem of limited treatment options for solid tumors.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}